drugset / Trial / NCT04915248
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
NaSingle-groupOpen-labelTreatment
Summary
It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma.
Timeline
- Start
- 2022-07-11
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Background | Bortezomib | Small molecule | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | — |